Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $50.42

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned a consensus recommendation of “Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $50.42.

A number of analysts have recently weighed in on DYN shares. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Robert W. Baird began coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Dirk Kersten sold 23,671 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the transaction, the director now directly owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This represents a 19.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,742 shares of company stock valued at $1,443,246. 20.77% of the stock is currently owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its holdings in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after buying an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after acquiring an additional 2,189,339 shares during the period. State Street Corp increased its stake in shares of Dyne Therapeutics by 13.8% during the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after purchasing an additional 440,890 shares during the last quarter. RTW Investments LP raised its holdings in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after purchasing an additional 431,503 shares during the period. Finally, RA Capital Management L.P. lifted its stake in Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 0.4 %

DYN stock opened at $23.56 on Monday. The firm has a market cap of $2.40 billion, a P/E ratio of -6.62 and a beta of 1.09. Dyne Therapeutics has a 1-year low of $12.33 and a 1-year high of $47.45. The business’s 50 day moving average is $28.02 and its 200-day moving average is $34.54.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Sell-side analysts forecast that Dyne Therapeutics will post -3.45 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.